294 related articles for article (PubMed ID: 29338080)
1. Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
O'Reilly EM; Lee JW; Lowery MA; Capanu M; Stadler ZK; Moore MJ; Dhani N; Kindler HL; Estrella H; Maynard H; Golan T; Segal A; Salo-Mullen EE; Yu KH; Epstein AS; Segal M; Brenner R; Do RK; Chen AP; Tang LH; Kelsen DP
Cancer; 2018 Apr; 124(7):1374-1382. PubMed ID: 29338080
[TBL] [Abstract][Full Text] [Related]
2. Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline
O'Reilly EM; Lee JW; Zalupski M; Capanu M; Park J; Golan T; Tahover E; Lowery MA; Chou JF; Sahai V; Brenner R; Kindler HL; Yu KH; Zervoudakis A; Vemuri S; Stadler ZK; Do RKG; Dhani N; Chen AP; Kelsen DP
J Clin Oncol; 2020 May; 38(13):1378-1388. PubMed ID: 31976786
[TBL] [Abstract][Full Text] [Related]
3. Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies.
Gray HJ; Bell-McGuinn K; Fleming GF; Cristea M; Xiong H; Sullivan D; Luo Y; McKee MD; Munasinghe W; Martin LP
Gynecol Oncol; 2018 Mar; 148(3):507-514. PubMed ID: 29352572
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
Lowery MA; Kelsen DP; Capanu M; Smith SC; Lee JW; Stadler ZK; Moore MJ; Kindler HL; Golan T; Segal A; Maynard H; Hollywood E; Moynahan M; Salo-Mullen EE; Do RKG; Chen AP; Yu KH; Tang LH; O'Reilly EM
Eur J Cancer; 2018 Jan; 89():19-26. PubMed ID: 29223478
[TBL] [Abstract][Full Text] [Related]
5. A Phase I/II Study of Veliparib (ABT-888) in Combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
Pishvaian MJ; Wang H; He AR; Hwang JJ; Smaglo BG; Kim SS; Weinberg BA; Weiner LM; Marshall JL; Brody JR
Clin Cancer Res; 2020 Oct; 26(19):5092-5101. PubMed ID: 32669374
[TBL] [Abstract][Full Text] [Related]
6. Complete remission, in BRCA2 mutation carrier with metastatic pancreatic adenocarcinoma, treated with cisplatin based therapy.
Sonnenblick A; Kadouri L; Appelbaum L; Peretz T; Sagi M; Goldberg Y; Hubert A
Cancer Biol Ther; 2011 Aug; 12(3):165-8. PubMed ID: 21613821
[TBL] [Abstract][Full Text] [Related]
7. A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
Lowery MA; Yu KH; Kelsen DP; Harding JJ; Bomalaski JS; Glassman DC; Covington CM; Brenner R; Hollywood E; Barba A; Johnston A; Liu KC; Feng X; Capanu M; Abou-Alfa GK; O'Reilly EM
Cancer; 2017 Dec; 123(23):4556-4565. PubMed ID: 28832976
[TBL] [Abstract][Full Text] [Related]
8. BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
Lohse I; Borgida A; Cao P; Cheung M; Pintilie M; Bianco T; Holter S; Ibrahimov E; Kumareswaran R; Bristow RG; Tsao MS; Gallinger S; Hedley DW
Br J Cancer; 2015 Jul; 113(3):425-32. PubMed ID: 26180923
[TBL] [Abstract][Full Text] [Related]
9. Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
Wattenberg MM; Asch D; Yu S; O'Dwyer PJ; Domchek SM; Nathanson KL; Rosen MA; Beatty GL; Siegelman ES; Reiss KA
Br J Cancer; 2020 Feb; 122(3):333-339. PubMed ID: 31787751
[TBL] [Abstract][Full Text] [Related]
10. Phase I Study of Veliparib (ABT-888) Combined with Cisplatin and Vinorelbine in Advanced Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer.
Rodler ET; Kurland BF; Griffin M; Gralow JR; Porter P; Yeh RF; Gadi VK; Guenthoer J; Beumer JH; Korde L; Strychor S; Kiesel BF; Linden HM; Thompson JA; Swisher E; Chai X; Shepherd S; Giranda V; Specht JM
Clin Cancer Res; 2016 Jun; 22(12):2855-64. PubMed ID: 26801247
[TBL] [Abstract][Full Text] [Related]
11. Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer (BROCADE3): a randomised, double-blind, placebo-controlled, phase 3 trial.
Diéras V; Han HS; Kaufman B; Wildiers H; Friedlander M; Ayoub JP; Puhalla SL; Bondarenko I; Campone M; Jakobsen EH; Jalving M; Oprean C; Palácová M; Park YH; Shparyk Y; Yañez E; Khandelwal N; Kundu MG; Dudley M; Ratajczak CK; Maag D; Arun BK
Lancet Oncol; 2020 Oct; 21(10):1269-1282. PubMed ID: 32861273
[TBL] [Abstract][Full Text] [Related]
12. Phase 1b study of a small molecule antagonist of human chemokine (C-C motif) receptor 2 (PF-04136309) in combination with nab-paclitaxel/gemcitabine in first-line treatment of metastatic pancreatic ductal adenocarcinoma.
Noel M; O'Reilly EM; Wolpin BM; Ryan DP; Bullock AJ; Britten CD; Linehan DC; Belt BA; Gamelin EC; Ganguly B; Yin D; Joh T; Jacobs IA; Taylor CT; Lowery MA
Invest New Drugs; 2020 Jun; 38(3):800-811. PubMed ID: 31297636
[TBL] [Abstract][Full Text] [Related]
13. Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
Golan T; Sella T; O'Reilly EM; Katz MH; Epelbaum R; Kelsen DP; Borgida A; Maynard H; Kindler H; Friedmen E; Javle M; Gallinger S
Br J Cancer; 2017 Mar; 116(6):697-702. PubMed ID: 28183138
[TBL] [Abstract][Full Text] [Related]
14. A multicenter, phase I/II trial of biweekly S-1, leucovorin, oxaliplatin and gemcitabine in metastatic pancreatic adenocarcinoma-TCOG T1211 study.
Chiang NJ; Tsai KK; Hsiao CF; Yang SH; Hsiao HH; Shen WC; Hsu C; Lin YL; Chen JS; Shan YS; Chen LT
Eur J Cancer; 2020 Jan; 124():123-130. PubMed ID: 31765987
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of the PARP Inhibitor Veliparib with Carboplatin or as a Single Agent in Patients with Germline
Somlo G; Frankel PH; Arun BK; Ma CX; Garcia AA; Cigler T; Cream LV; Harvey HA; Sparano JA; Nanda R; Chew HK; Moynihan TJ; Vahdat LT; Goetz MP; Beumer JH; Hurria A; Mortimer J; Piekarz R; Sand S; Herzog J; Van Tongeren LR; Ferry-Galow KV; Chen AP; Ruel C; Newman EM; Gandara DR; Weitzel JN
Clin Cancer Res; 2017 Aug; 23(15):4066-4076. PubMed ID: 28356425
[No Abstract] [Full Text] [Related]
16. CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study.
O'Hara MH; O'Reilly EM; Varadhachary G; Wolff RA; Wainberg ZA; Ko AH; Fisher G; Rahma O; Lyman JP; Cabanski CR; Mick R; Gherardini PF; Kitch LJ; Xu J; Samuel T; Karakunnel J; Fairchild J; Bucktrout S; LaVallee TM; Selinsky C; Till JE; Carpenter EL; Alanio C; Byrne KT; Chen RO; Trifan OC; Dugan U; Horak C; Hubbard-Lucey VM; Wherry EJ; Ibrahim R; Vonderheide RH
Lancet Oncol; 2021 Jan; 22(1):118-131. PubMed ID: 33387490
[TBL] [Abstract][Full Text] [Related]
17. A phase I trial of cabozantinib and gemcitabine in advanced pancreatic cancer.
Zhen DB; Griffith KA; Ruch JM; Camphausen K; Savage JE; Kim EJ; Sahai V; Simeone DM; Zalupski MM
Invest New Drugs; 2016 Dec; 34(6):733-739. PubMed ID: 27439894
[TBL] [Abstract][Full Text] [Related]
18. A 67-year-old woman with BRCA 1 mutation associated with pancreatic adenocarcinoma.
Lowery M; Shah MA; Smyth E; Epstein A; Segal A; Rosengarten O; Isacson R; Drukker L; Keinan A; Rachkiman M; Reissman P; Gabizon A; Kelsen D; O'Reilly EM
J Gastrointest Cancer; 2011 Sep; 42(3):160-4. PubMed ID: 20711688
[TBL] [Abstract][Full Text] [Related]
19. Germline BRCA mutations in Asian patients with pancreatic adenocarcinoma: a prospective study evaluating risk category for genetic testing.
Lee K; Yoo C; Kim KP; Park KJ; Chang HM; Kim TW; Lee JL; Lee W; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Shin SH; Hwang DW; Song KB; Lee JH; Kim SC; Ryoo BY
Invest New Drugs; 2018 Feb; 36(1):163-169. PubMed ID: 28782087
[TBL] [Abstract][Full Text] [Related]
20. Nab-paclitaxel plus gemcitabine with or without capecitabine and cisplatin in metastatic pancreatic adenocarcinoma (PACT-19): a randomised phase 2 trial.
Reni M; Zanon S; Peretti U; Chiaravalli M; Barone D; Pircher C; Balzano G; Macchini M; Romi S; Gritti E; Mazza E; Nicoletti R; Doglioni C; Falconi M; Gianni L
Lancet Gastroenterol Hepatol; 2018 Oct; 3(10):691-697. PubMed ID: 30220407
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]